Guilford's Wafer Implants Improve Survival of Brain Cancer Patients
BALTIMORE, Md--The results of a phase III double-blind trial of Guilford Pharmaceutical Inc.'s Gliadel have been published in Lancet (April 22, 1995). In patients with malignant brain tumors, 6-month median survival rates increased from 23 weeks with placebo to 31 weeks with Gliadel treatment, the company said. For patients with glioblastoma multiforme, the increase was from 20 weeks to 28 weeks, a 55% improvement.
BALTIMORE, Md--The results of a phase III double-blind trial ofGuilford Pharmaceutical Inc.'s Gliadel have been published inLancet (April 22, 1995). In patients with malignant brain tumors,6-month median survival rates increased from 23 weeks with placeboto 31 weeks with Gliadel treatment, the company said. For patientswith glioblastoma multiforme, the increase was from 20 weeks to28 weeks, a 55% improvement.
Gliadel is a biodegradable polymer wafer containing carmustinein the polymer matrix. Up to eight wafers are implanted into thecavity created by tumor removal, thus overcoming the limitationsof IV carmustine.
The trial, led by Henry Brem, MD, of Johns Hopkins, involved 222patients at 27 centers.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Elevating the Quality of Cancer Care via Cross-Department Collaboration
Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.
